Veloxis Pharmaceuticals Showcases Breakthrough Research at World Transplant Congress 2025

Veloxis Pharmaceuticals, Inc., a specialty pharmaceutical company under Asahi Kasei, is making headlines as it prepares to present significant new findings at the upcoming World Transplant Congress (WTC) on August 5, 2025. This congress, held in San Francisco, is a cornerstone event in the field of transplantation and is organized by the American Society of Transplant Surgeons, the American Society of Transplantation, and The Transplantation Society.

The focus of Veloxis's presentation is VEL-101, also known as pegrizeprument, a novel subcutaneous CD28 co-stimulation blocker being developed to improve maintenance immunosuppression for kidney transplant recipients. This therapy aims to enhance long-term transplant outcomes, a critical aim within the transplantation community.

Innovative Research Findings

The pivotal study, entitled "Subcutaneous Administration of a CD28 Co-stimulation Blocker Demonstrates Efficacy in an NHP Model of Kidney Allotransplantation," will be delivered by Dr. Daniel Schuster, a General Surgery Resident at Duke University Medical Center. Findings from this preclinical study indicate that administering pegrizeprument significantly improved rejection-free survival in non-human primate models when compared to those that received no immunosuppression (P=0.0128). Moreover, combining this new therapy with standard immunosuppressive regimens mirrored the success seen with traditional treatments, like tacrolimus, while reducing donor-specific antibodies and suggesting a potentially improved safety profile.

Dr. Allan D. Kirk, Chair of Surgery at Duke University, expressed optimism regarding these results, highlighting the significant implications for immunosuppression practices in transplant medicine. He noted, "The study demonstrates clear efficacy of pegrizeprument in preventing rejection while potentially reducing the overall burden of immunosuppression. This could be revolutionary in enhancing the quality of life for transplant patients."

Spotlight on Veloxis at the WTC

Veloxis CEO, Stacy Wheeler, emphasized the importance of this platform, stating, "The World Transplant Congress brings together the brightest minds in transplantation. We are incredibly proud to have pegrizeprument featured at this year's congress. Our research's selection reflects our meaningful progress in the realm of innovative immunosuppressive therapies, marking an exciting milestone for Veloxis."

Apart from the presentation, Veloxis will also have a presence at booth #501 during the congress, providing attendees an opportunity to learn more about their ongoing research and advancements in transplant-related pharmaceuticals.

About Pegrizeprument

Pegrizeprument functions as a pegylated monoclonal antibody fragment, capable of blocking CD28-mediated T cell activation without inhibiting CTLA-4, an essential protein supporting immune regulation. This dual mechanism not only directly inhibits unwanted immune responses but also preserves natural regulatory functions within the immune system. Registered as FR104, Veloxis obtained the rights to develop this compound from OSE Immunotherapeutics, reaffirming their commitment to expanding treatment options for transplant patients.

Veloxis's Commitment

Veloxis Pharmaceuticals is dedicated to enhancing the lives of transplant patients. With its headquarters in Cary, North Carolina, the company manages a global pipeline of therapies tailored for transplant patients and those suffering from related serious diseases. The goal remains straightforward yet ambitious: to innovate and illuminate pathways to better long-term outcomes for transplant recipients across the world.

In conclusion, Veloxis Pharmaceuticals is poised to make a significant impact at the World Transplant Congress 2025. By presenting new data on pegrizeprument, the company aims to initiate discourse surrounding advanced immunosuppressive therapies that could reshape the future of kidney transplantation.